ECV - Epihunter Clinical Validation (ECV)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Leuven, Belgium
- UZ Leuven
-
-
-
-
-
Dianalund, Denmark
- Danish Epilepsy Center
-
-
-
-
-
Tbilisi, Georgia
- Institute of Neurology and Neuropsychology
-
-
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Boston Children's Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects should have an indication of having absence seizures
- Subjects should be admitted for video EEG monitoring as part of their clinical practice
- Age > 4 years
Exclusion Criteria:
- Head circumference should be compatible for wearable EEG device (40-70cm)
- The subject should be able to understand instructions and refrain from removing the device from its head
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: All subjects
Subjects that undergo a clinical video EEG are asked to additionally wear a wearable EEG headband for up to 2 periods of 4h during the video EEG.
|
Subjects wear epihunter during routine video EEG
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sensitivity for electrographic seizures of study device compared to video EEG
Time Frame: 9 months
|
The sensitivity for electrographic seizures by the study device compared to manually annotated electrographic seizures on non-video EEG is > 0.90 (median sensitivity per patient)
|
9 months
|
|
Number of false alarms by study device per hour
Time Frame: 9 months
|
The number of false alarms by the study device < 0.1 per hour (median false detection rate per recording)
|
9 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility testing of automated behavioral testing triggered by automated detection
Time Frame: 3 months
|
Assess if automated behavioral testing triggered by automated detection can be used to automatically assess awareness during an absence seizure.
Successful if subjects DO NOT react to the testing during an unaware seizure, and DO react during an aware seizure.
|
3 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Dirk Loeckx, PhD, Epihunter NV
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- EPI2019B
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.